Format

Send to

Choose Destination
J Affect Disord. 2019 Sep 1;256:267-277. doi: 10.1016/j.jad.2019.06.008. Epub 2019 Jun 3.

Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial.

Author information

1
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-B232; PO Box 19024; Seattle, WA 98109, USA. Electronic address: jheffner@fredhutch.org.
2
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
3
Pfizer, New York, NY, USA.
4
University of California, San Diego, CA, USA.
5
PAREXEL International on behalf of GlaxoSmithKline, Research Triangle Park, NC, USA.
6
University College, London, UK.

Abstract

OBJECTIVES:

Post hoc analyses of EAGLES data to examine safety and efficacy of first-line smoking cessation pharmacotherapies in smokers with bipolar disorders (BD).

METHODS:

Smokers with BD I/II (n = 285; 81.4% with BD I) and a comparison nonpsychiatric cohort (NPC; n = 2794) were randomly assigned to varenicline, bupropion, nicotine replacement therapy (NRT), or placebo for 12 weeks, plus weekly counseling. Primary outcomes were occurrence of moderate to severe neuropsychiatric adverse events (NPSAEs) and Weeks 9-12 biochemically-confirmed continuous abstinence (CA) rates.

RESULTS:

For BD smokers, NPSAE risk differences versus placebo were: varenicline, 6.17 (95% CI: -7.84 to 20.18); bupropion, 4.09 (-8.82 to 16.99); NRT, -0.56 (-12.34 to 11.22). ORs for Weeks 9-12 CA, comparing active medication to placebo among BD smokers were: varenicline, 2.61 (0.68-9.95); bupropion, 1.29 (0.31-5.37), NRT, 0.71 (0.14-3.74). Pooling across treatments, NPSAE occurrence was higher (10.7% versus 2.3%; P < 0.001) and CA rates were lower (22.8% versus 13.3%; P = 0.008) in BD than NPC.

LIMITATIONS:

Study not powered to detect differences in safety and efficacy in the BD subcohort; generalizability limited to stably treated BD without current substance use disorders.

CONCLUSIONS:

Smokers with BD had higher risk of NPSAEs and were less likely to quit overall than NPC smokers. Among smokers with BD, NPSAE risk difference estimates for active treatments versus placebo ranged from 1% lower to 6% higher. Efficacy of varenicline in smokers with BD was similar to EAGLES main outcomes; bupropion and NRT effect sizes were descriptively lower. Varenicline may be a tolerable and effective cessation treatment for smokers with BD.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier (https://clinicaltrials.gov/): NCT01456936.

KEYWORDS:

Abbreviations: BD, bipolar disorders; Bipolar disorder; CA, continuous abstinence; CAR, continuous abstinence rate; Efficacy; NPC, nonpsychiatric cohort; NPSAE, neuropsychiatric adverse event; PPA, point prevalence abstinence; Safety; Smoking cessation; Varenicline

PMID:
31195244
DOI:
10.1016/j.jad.2019.06.008

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center